2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

patients are cared for completely with aggressive palliation
of symptoms to maximize their remaining time. Celiac
plexus neurolysis improves pain in the majority of APC
patients and should be moved earlier in the analgesic
paradigm. Antiemetics continue to evolve for maximal prevention
of CINV, including olanzapine in recent studies.
Nutritional status remains important to patients and families;
weight loss related to undiagnosed pancreas exocrine
Author’s Disclosures of Potential Conflicts of Interest
Author
Lauren A. Wiebe*
*No relevant relationships to disclose.
Employment or
Leadership
Positions
Consultant or
Advisory Role
1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer
J Clin. 2012;62:10-29.
2. Chochinov HM. Dying, dignity and new horizons in palliative end-of-life
care. CA Cancer J Clin. 2006;56:84-103.
3. Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in
unresectable pancreatic cancer. Am J Gastroenterol. 2007;102:430-438.
4. Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind,
controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis
to prevent pain progression in patients with newly diagnosed, painful,
inoperable pancreatic cancer. J Clin Oncol. 29:3541-3546.
5. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society
of Clinical Oncology Practice Guideline Update. J Clin Oncol. 2011;29:4189-
4198.
6. National Comprehensive Cancer Network. Clinical Practice Guidelines
in Oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.
asp#supportive. Accessed February 29, 2012.
7. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the
prevention of chemotherapy-induced nausea and vomiting: A randomized
phase III trial. J Support Oncol. 2011;9:188-195.
8. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention
of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res.
2009;29:131.
9. Donthireddy KR, Ailawadhi S, Nasser E, et al. Malignant gastroparesis:
Pathogenesis and management of an underrecognized disorder. J Support
Oncol. 2007;5:355-363.
10. Juernink SM, van Eijck CHJ, Steyerberg EW, et al. Stent versus
gastrojejunostomy for the palliation of gastric outlet obstruction: A systematic
review. BMC Gastroenterol. 2007;7:18.
11. Ripamonti CT, Easson AM, Gerdes H. Management of malignant bowel
obstruction. Eur J Cancer. 2008;44:1105-1115.
12. Chung M and Kozuch P. Treatment of malignant ascites. Curr Treat
Options Oncol. 2008;9:215-233.
248
insufficiency improves with aggressive enzyme supplementation.
Bowel dysfunction from gastroparesis or malignant
obstruction is treatable with palliative interventions. Finally,
the existential and psychosocial concerns of patients
facing death from pancreatic cancer should be addressed in
a holistic manner. Early integration of palliative care will
help patients achieve the best quality of life in the face of
this unfortunate diagnosis.
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
LAUREN A. WIEBE
Other
Remuneration
13. Halloran CM, Cox TF, Chauhan S, et al. Partial pancreatic resection for
pancreatic malignancy is associated with sustained pancreatic exocrine
failure and reduced quality of life: A prospective study. Pancreatology.
2011;11:535-545.
14. Dominguez-Munoz JE. Pancreatic exocrine insufficiency: Diagnosis
and treatment. J Gastroenterol Hepatol. 2011;26 Suppl. 2:12-16.
15. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer
cachexia: Clinical implications, diagnosis, and emerging treatment strategies.
Annu Rev Med. 2011;62:265-279.
16. Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations
for cancer fatigue, anorexia, depression and dyspnea. J Clin Oncol. 2008;26:
3886-3895.
17. Berenstein G, Ortiz Z. Megestrol acetate for treatment of anorexiacachexia
syndrome. Cochrane Database of Systematic Reviews 2005, Issue 2.
Art. No.: CD004310.
18. Davis M, Lasheen W, Walsh D, et al. A phase II dose titration study of
thalidomide for cancer-associated anorexia. J Pain Symptom Manage. 2012;
43:78-86.
19. Boutros C, Somasundar P, Razzak A, et al. Omega-3 fatty acids:
Investigations from cytokine regulation to pancreatic cancer gene suppression.
Arch Surg. 2010;145:515-520.
20. Clark KL, Loscalzo M, Trask PC, et al. Pyschological distress in
patients with pancreatic cancer—an understudied group. Pychooncology.
2010;19:1313-1320.
21. Mayr M, Schmid RM. Pancreatic cancer and depression: Myth and
truth. BMC Cancer. 2010;10:569.
22. Turaga KT, Malafa MP, Jacobsen PB, et al. Suicide in patients with
pancreatic cancer. Cancer. 2011;117:642-647.
23. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical
Oncology Provisional Clinical Opinion: The Integration of Palliative Care into
Standard Oncology Care. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.
38.5161. Accessed February 29, 2012.